Home › Funds › Fairmount Funds Management LLC › ZBIO

Fairmount Funds Management LLC position in ZBIO

ZENAS BIOPHARMA INC COM · Health Care

Fairmount Funds Management LLC reported holding 2,359,025 shares of ZBIO (ZENAS BIOPHARMA INC COM) in its Q2 2026 13F filing — a position valued at US$59.9M, representing 3.96% of its reported portfolio and ranking #8 among its reported holdings. Fairmount Funds Management LLC has disclosed ZBIO holdings in 8 of the last 8 reported quarters, going back to Q3 2024.

Latest position (Q2 2026)2.36M sh
Reported value held$59.87M
Portfolio Weight3.96%
First reportedQ3 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Fairmount Funds Management LLC's ZBIO position evolved

Fairmount Funds Management LLC first disclosed a stake in ZBIO in Q3 2024 at 1,892,806 shares (US$32.0M). The position peaked in Q4 2025 at 2,209,025 shares, worth US$80.2M. Across 8 filings, Fairmount Funds Management LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 2,359,025 shares valued at US$59.9M.

Quarter by quarter

QuarterSharesValueChange
Q3 2024 1.89M $32.03M New
Q4 2024 1.89M $15.50M Hold
Q1 2025 1.89M $14.95M Hold
Q2 2025 1.89M $18.34M Hold
Q3 2025 1.89M $42.02M Hold
Q4 2025 2.21M $80.21M Add
Q1 2026 2.36M $46.12M Add
Q2 2026 2.36M $59.87M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ZBIO and 13F data

ZBIO (ZENAS BIOPHARMA INC COM) is a Health Care company. 68 other funds we track also report a position in ZBIO — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$127.9M), NEA Management Company, LLC (US$102.1M), Enavate Sciences GP, LLC (US$99.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ZBIO

All ZBIO fund holders →

FAQ

How long has Fairmount Funds Management LLC held ZBIO?

Fairmount Funds Management LLC has disclosed ZBIO holdings in 8 of the last 8 reported quarters, going back to Q3 2024.

What is Fairmount Funds Management LLC's current position in ZBIO?

As of Q2 2026, Fairmount Funds Management LLC holds 2.36M shares of ZBIO (ZENAS BIOPHARMA INC COM), valued at $59.87M, representing 3.96% of its reported portfolio and ranking #8.

Has Fairmount Funds Management LLC been buying or selling ZBIO?

In the latest 13F filing (Q2 2026), Fairmount Funds Management LLC held unchanged its position in ZBIO. The position peaked in Q4 2025 at 2.21M shares.

Which other funds hold ZBIO?

Other major institutional holders of ZBIO include SR ONE CAPITAL MANAGEMENT, LP, NEA Management Company, LLC, Enavate Sciences GP, LLC, among 68 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.